Physician profile
Rohan Gupta
NPI 1326482860
$83,579.13
in general payments reported to CMS, 2019-2025
56 companies · $16K in 2025
The $16K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,043 · 2020: $1,006 · 2021: $7,317 · 2022: $2,663 · 2023: $18K · 2024: $35K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $34K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Travel and Lodging: $5,758 · Food and Beverage: $3,814 · Education: $72.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $33,626.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,280.00 |
| Travel and Lodging | $5,758.49 |
| Food and Beverage | $3,813.61 |
| Education | $72.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $29,165.68 | 2023-2025 | Keytruda, Keytruda Qlex |
| Daiichi Sankyo INC. | $14,175.34 | 2020-2025 | Enhertu, Datroway, Vanflyta |
| Seagen INC. | $7,499.87 | 2023 | Adcetris |
| Pfizer INC. | $5,871.48 | 2020-2025 | |
| Rigel Pharmaceuticals, INC. | $2,585.99 | 2019 | |
| Kyowa Kirin, INC. | $2,495.20 | 2023-2024 | Poteligeo |
| Novartis Pharmaceuticals Corporation | $2,488.18 | 2019-2025 | |
| Beigene USA, INC. | $2,317.37 | 2022-2025 | Brukinsa |
| Amgen INC. | $2,078.68 | 2023 | Blincyto, Kyprolis |
| Blueprint Medicines Corporation | $1,947.50 | 2021 | |
| Celgene Corporation | $1,811.15 | 2019-2025 | Reblozyl, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $1,723.25 | 2024-2025 | Imfinzi, Enhertu, Calquence |
| E.R. Squibb & Sons, L.L.C. | $1,718.12 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $1,387.50 | 2025 | Tecvayli |
| Incyte Corporation | $1,153.11 | 2022-2025 | Jakafi |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,043.21 | 2022-2023 | |
| Glaxosmithkline, LLC. | $793.96 | 2019-2025 | Ojjaara, Jemperli, Shingrix |
| Genzyme Corporation | $576.91 | 2021-2025 | |
| Abbvie INC. | $412.79 | 2019-2025 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Acera Surgical, INC. | $153.48 | 2025 | Restrata Wound Matrix |
| Avita Medical Americas, LLC | $151.04 | 2025 | Permeaderm, Recell, Cohealyx |
| Penumbra, INC. | $129.44 | 2025 | Indigo System |
| Takeda Pharmaceuticals U.S.A., INC. | $124.43 | 2019-2025 | Alunbrig, Fruzaqla, Ninlaro |
| Array Biopharma INC | $104.47 | 2024-2025 | Mektovi, Braftovi, Xalkori |
| Springworks Therapeutics, INC. | $103.36 | 2024-2025 | Ogsiveo |
| Astellas Pharma US INC | $102.31 | 2022-2025 | Xospata, Padcev |
| Alexion Pharmaceuticals, INC. | $95.72 | 2019-2024 | Ultomiris |
| Eisai INC. | $87.46 | 2022-2025 | |
| Tempus Ai, INC | $81.54 | 2024-2025 | Xt Cdx |
| Lilly USA, LLC | $71.20 | 2022 | |
| Kite Pharma, INC. | $70.53 | 2022-2024 | Yescarta |
| Janssen Biotech, INC. | $67.20 | 2024-2025 | Tecvayli |
| Sanofi-Aventis U.S. LLC | $66.99 | 2019-2021 | |
| Adaptive Biotechnologies Corporation | $66.77 | 2022-2023 | Clonoseq |
| Pharmaessentia USA Corporation | $64.59 | 2023 | Besremi |
| Sun Pharmaceutical Industries INC. | $53.25 | 2023-2025 | Yonsa, Odomzo |
| Genentech USA, INC. | $51.99 | 2019-2023 | Tecentriq |
| Morphosys, US INC. | $43.89 | 2023 | Monjuvi |
| Janssen Pharmaceuticals, INC | $43.88 | 2019-2021 | |
| Exelixis INC. | $43.80 | 2025 | Cabometyx |
| Aveo Pharmaceuticals, INC. | $42.21 | 2023-2025 | Fotivda |
| Gilead Sciences, INC. | $36.22 | 2023 | Trodelvy |
| Siemens Medical Solutions USA, INC. | $35.64 | 2019 | |
| Beone Medicines USA, INC. | $32.83 | 2025 | Tevimbra |
| Pharmacyclics LLC, An Abbvie Company | $25.84 | 2023 | Imbruvica, Epkinly |
| Apellis Pharmaceuticals, INC. | $24.05 | 2022 | |
| Geron Corporation | $21.41 | 2024 | Rytelo |
| Agios Pharmaceuticals, INC. | $21.11 | 2023 | Pyrukynd |
| Tesaro, INC. | $19.39 | 2019 | |
| Puma Biotechnology, INC. | $19.18 | 2023 | |
| Deciphera Pharmaceuticals INC. | $18.78 | 2024 | Qinlock |
| Sobi, INC | $16.24 | 2024 | |
| Karyopharm Therapeutics INC. | $15.48 | 2020 | |
| Secura Bio, INC. | $14.19 | 2023 | Copiktra |
| Acrotech Biopharma INC. | $13.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohan Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.